Metraipolis › archive › dc_8a473a1b77fc
Tumor-specific major histocompatibility-II expression predicts pathological complete response to atezolizumab combined to chemotherapy in triple-negative… — Europe PMC PMID:41022779
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41022779
- DOI
- 10.1038/s41523-[numero omesso]-6
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-09T17:37:10.267Z
- SHA-256 of the archived text
1e5d7363ef082a882a061be2cfedae73e8c602dee5e4a19e915f68c681b29e3f- Stable URL of this page
https://metraipolis.com/documento/dc_8a473a1b77fc
How to cite
Tumor-specific major histocompatibility-II expression predicts pathological complete response to atezolizumab combined to chemotherapy in triple-negative… — Europe PMC PMID:41022779 — Europe PMC (en), https://europepmc.org/article/MED/41022779 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_8a473a1b77fc (Metraipolis archive dc_8a473a1b77fc, sha256 1e5d7363ef082a882a061be2cfedae73e8c602dee5e4a19e915f68c681b29e3f)
BibTeX
@misc{dc8a473a1b77fc,
title = {Tumor-specific major histocompatibility-II expression predicts pathological complete response to atezolizumab combined to chemotherapy in triple-negative… — Europe PMC PMID:41022779},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41022779},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_8a473a1b77fc; sha256 1e5d7363ef082a882a061be2cfedae73e8c602dee5e4a19e915f68c681b29e3f},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41022779. Agents can read the archived copy with the MCP tool read_document.